

**SARC Semiannual Meeting Agenda**  
**Friday, June 3, 2016**

|                    |   |  |
|--------------------|---|--|
| <b>8:00</b>        | <b>Opening Remarks</b>  |  |
|                    | Denise Reinke   |  |
| <b>8:15</b>        | <b>Chawla Rosenfeld Developmental Therapeutics Symposium</b>  |  |
|                    | Introduction  | Robert Maki/David Kirsch   |
|                    | Astrocyte-derived Exosomal microRNA Primes Brain Metastasis Outgrowth   | Dihua Yu   |
|                    | Exosomes as markers for Kaposi Sarcoma progression  | Dirk Dittmer   |
|                    | Circulating tumor DNA: Overview and Applications for Sarcoma  | Max Diehn  |
|                    | <i>Discussion/Q&amp;A</i>   | Panel  |
| <b>9:45</b>        | <b>Career Development Program</b>   |  |
|                    | 2016 Awards   | Richard Gorlick & Lee Helman   |
| <b>10:00-10:20</b> | <b>Break</b>  |  |
| <b>10:20-10:35</b> | <b>SARC Sarcoma SPORE</b>   |  |
|                    | Update  | Raphael Pollock  |
| <b>10:35</b>       | <b>SARC Clinical Trials</b>   |  |
|                    | Clinical Trials Update  | Scott Okuno  |
|                    | <b>SARC016:</b> Phase 2 trial of bevacizumab & everolimus in unresectable or metastatic MPNST                                   | Brigitte Widemann  |
|                    | <b>SARC018-SPORE01:</b> Phase 2 trial of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma | Edwin Choy & Shreyaskumar Patel  |
|                    | <b>SARC021:</b> Phase 3 trial of TH-302+doxorubicin versus doxorubicin in advanced/metastatic STS                               | William Tap  |
|                    | <b>SARC023:</b> Phase 1/2 trial of ganetespib & sirolimus in unresectable or metastatic MPNST                                   | AeRang Kim   |
|                    | <b>SARC024:</b> Phase 2 trial of regorafenib in refractory lipo, osteo and Ewing/Ewing-like sarcomas                            | Robert Maki,<br>Richard Riedel,<br>Steven Attia &<br>Christopher Ryan/Lara Davis |
|                    | <b>SARC025-SPORE03:</b> Phase 1 trial of niraparib and temozolomide or irinotecan in incurable Ewing sarcoma.                   | Rashmi Chugh & Sandra Straus   |
|                    | <b>SARC028:</b> Phase 2 trial of the anti-PD1 antibody pembrolizumab (MK-3475) in patients with advanced sarcomas               | Melissa Burgess & Hussein Tawbi  |
| <b>11:55</b>       | <b>Closing Remarks/Adjourn</b>  |  |